Editas Medicine Plans Human Trial After Gene Therapy Slashed LDL 90% in Primate Study
Editas Medicine (NASDAQ:EDIT) plans human trials after its gene therapy reduced LDL cholesterol by 90% in primates. The company raised $125M, extending its cash runway to 2028. CFO Amy Parison said funds will support trial completion. CEO O'Neill noted potential approval path for LDL reduction, pending regulatory agreement.




